EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial

Jennifer S Gewandter, Eva Culakova, Jenae N Davis, Umang Gada, Joseph J Guido, James D Bearden, Brain Burnette, Dhaval Shah, Gary R Morrow, Karen Mustian, Kathleen A Sluka, Nimish Mohile

The Journal of Pain · 2024-05 · 25 (5) · 104431

DOI: 10.1016/j.jpain.2023.11.014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Pain, 2024-05. Verfasst von Jennifer S Gewandter und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, New York. Hauptthemen laut MEDLINE: Transcutaneous Electric Nerve Stimulation, Peripheral Nervous System Diseases, Proof of Concept Study, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 30 to 60% of people who receive neurotoxic chemotherapy. CIPN is associated with impaired quality of life and function and has few effective treatments. This 6-site, subject and assessor-blinded randomized clinical trial (RCT) was designed to assess 1) preliminary efficacy (ie, alpha pre-specified at .2) of a wearable, app-controlled, transcutaneous electrical nerve stimulation (TENS) device for chronic CIPN and 2) feasibility of conducting a confirmatory trial within the National Cancer Institute Community Oncology Research Program (NCORP) (NCT04367480). The primary outcome was the EORTC-CIPN20. The main secondary outcomes were individual symptoms assessed daily (via 0-10 numeric rating scales). The primary analysis was an analysis of covariance (outcome: EORTC-CIPN20, fixed effect: arm, covariates: baseline EORTC-CIPN20 and site). Secondary analyses used a similar analysis of covariance models (excluding site) for each symptom on subgroups of subjects with ≥4 out of 10 for that symptom at baseline. 142 eligible subjects were randomized and received a device; 130 (91%) completed the study. The difference between groups in the EORCT-CIPN20 at the endpoint (placebo-active) was 1.05 (95% Confidence Interval: -.56, 2.67; P = .199). The difference between groups for the individual symptoms was as follows: hot/burning pain: 1.37 (-.33, 3.08; P = .112), sharp/shooting pain: 1.21 (-.37, 2.79; P = .128), cramping: 1.35 (-.32, 3.02; P = .110), tingling: .23 (-.61, 1.08; P = .587), numbness: .27 (-.51, 1.05; P = .492). An RCT of an app-controlled TENS device for chronic CIPN with excellent retention is feasible in the NCORP. Preliminary efficacy evidence suggests that TENS is promising for pain and cramping from CIPN. A confirmatory RCT of TENS for painful CIPN is highly warranted. PERSPECTIVE: Daily, home-based TENS therapy demonstrates promising efficacy for painful CIPN symptoms in this proof-of-concept randomized clinical trial. Future confirmatory trial is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcutaneous Electric Nerve StimulationPeripheral Nervous System DiseasesProof of Concept StudyAntineoplastic AgentsHumansFemaleMaleMiddle AgedAgedAdultWearable Electronic DevicesFeasibility Studies

Stichwörter der Autor:innen

Chemotherapy-induced peripheral neuropathyRandomized clinical trialTranscutaneous electrical nerve stimulation

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, New York.
  • Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, New York.
  • Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, New York.
  • Upstate Carolina Consortium Community Oncology Research Program (UPSTATE), Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina.
  • Cancer Research of Wisconsin and Northern Michigan NCORP, Green Bay, Wisconsin.
  • Helen F. Graham Cancer Center and Research Institute, Christiana Care, Newark, Delaware.

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Gewandter, J. S., Culakova, E., Davis, J. N., Gada, U., Guido, J. J., Bearden, J. D., Burnette, B., Shah, D., Morrow, G. R., Mustian, K., Sluka, K. A., & Mohile, N. (2024). Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial. The Journal of Pain, 25(5), 104431. https://doi.org/10.1016/j.jpain.2023.11.014

Vancouver

Gewandter JS, Culakova E, Davis JN, Gada U, Guido JJ, Bearden JD, et al. Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial. The Journal of Pain. 2024;25(5):104431. doi:10.1016/j.jpain.2023.11.014

BibTeX
@article{Gewandter2024,
  author = {Gewandter, Jennifer S and Culakova, Eva and Davis, Jenae N and Gada, Umang and Guido, Joseph J and Bearden, James D and Burnette, Brain and Shah, Dhaval and Morrow, Gary R and Mustian, Karen and Sluka, Kathleen A and Mohile, Nimish},
  title = {Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial},
  journal = {The Journal of Pain},
  year = {2024},
  volume = {25},
  number = {5},
  pages = {104431},
  doi = {10.1016/j.jpain.2023.11.014}
}
Kostenlos starten →